Targets › VEGFR2
5 programs from 5 companies in 11 trials: 4 Phase 2, 4 Phase 1, 3 Phase 3; Oncology, Ophthalmology; next expected readout Dec 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. (UniProt, P35968)
Open in Phaseline: the race on VEGFR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics | 4D-150 AAV-based gene therapy delivering miRNA targeting VEGF-C and codon-optimized aflibercept s | VEGFA, VEGFC, VEGFR2 | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Diabetic Macular Edema … | Mar 2027 |
| Beijing Scitech-Mq Pharmaceuticals | ST-1898 Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI | VEGFR2, MET, AXL, PDGFRA, RET | Phase 2 | Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell Carcinoma | Dec 2026 |
| Fei Gao | Donafenib Multi-kinase inhibitor targeting FGFR and VEGFR | FGFR1, VEGFR1, VEGFR2, VEGFR3 | Phase 2 | Hepatocellular Carcinoma with PVTT | Dec 2026 |
| Karie Runcie | Zanzalintinib (XL092) Multi-targeted receptor tyrosine kinase inhibitor targeting VEGF receptors | VEGFR1, VEGFR2, VEGFR3 | Phase 2 | Advanced Renal Cell Carcinoma | Dec 2027 |
| Etnova Therapeutics | ETN101 Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB | FLT3, KIT, VEGFR2, PDGFRB | Phase 1 | Hepatocellular Carcinoma | Mar 2027 |
Advanced Renal Cell Carcinoma (2) Differentiated Thyroid Carcinoma (1) Unresectable or Metastatic Melanoma (1) Macular Neovascularization Secondary to Age-Related Macular Degeneration (1) Neovascular Age-Related Macular Degeneration (nAMD) (1) Diabetic Macular Edema (DME) (1) Diabetic Macular Edema (1) Neovascular (Wet) Age-Related Macular Degeneration (1) Hepatocellular Carcinoma (1) Hepatocellular Carcinoma with PVTT (1)
small molecule (3), mixed (2)
Beijing Scitech-Mq Pharmaceuticals (1) Karie Runcie (1) 4D Molecular Therapeutics (1) Etnova Therapeutics (1) Fei Gao (1)
VEGFR1 (2) VEGFR3 (2) MET (1) AXL (1) PDGFRA (1) RET (1) VEGFA (1) VEGFC (1) FLT3 (1) KIT (1) PDGFRB (1) FGFR1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.